Climber Capital
ABBV icon

Climber Capital’s AbbVie ABBV Stock Holding History

Climber Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$222K Hold
897
– – 0.14% 66
2026
Q2 		$225K Sell
897
-1,855
-67% -$399K 0.14% 62
2026
Q1 		$598K Buy
2,752
+1,855
+207% +$411K 0.39% 52
2025
Q4 		$205K Buy
+897
New +$204K 0.13% 58

Other funds holding ABBV

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Asset Management One
Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return
B. Metzler seel. Sohn & Co
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.5B AUM 29.17% 1-Year Est. Return

Climber Capital's ABBV Position: Q3 2026 in Review

Climber Capital held its AbbVie (ABBV) position steady in Q3 2026 at 897 shares worth $222K. The position accounts for 0.14% of the portfolio, ranked #66.

Climber Capital first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. The position peaked at $598K in Q1 2026. 1,999 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Climber Capital held 897 shares of AbbVie worth $222K as of Q3 2026.
  • Climber Capital left its AbbVie share count unchanged in Q3 2026.
  • AbbVie made up 0.14% of Climber Capital's portfolio in Q3 2026, its #66 holding.
  • Climber Capital first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • Climber Capital's AbbVie position peaked at $598K in Q1 2026.
  • 1,999 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Climber Capital's 13F filing for Q3 2026, filed 20 Oct 2026.